The bill, Section 150 of Chapter 178 of the Acts of 2024, mandates the Secretary of Veterans Services to establish a working group focused on exploring alternative mental health therapies for veterans, specifically psychedelic therapies such as psilocybin, ketamine, and MDMA. The group will assess the effectiveness of these treatments for veterans suffering from mental health disorders, including PTSD and depression, by reviewing existing literature and clinical trials. The bill outlines the composition of the working group, which will include representatives from medical centers, health insurance companies, veterans services organizations, and experts in the field. The findings from this group aim to inform legislative action and create a framework for the safe and regulated use of these therapies in Massachusetts.

Additionally, the bill addresses the current challenges surrounding access to psychedelic-assisted therapies, particularly for veterans, who often face financial barriers due to the classification of these substances as Schedule I controlled substances. It highlights the need for a regulatory framework to ensure equitable access and proposes the establishment of new Category III CPT codes for psychedelic therapy to facilitate documentation and data collection. The bill also emphasizes the importance of developing standards for training and clinical practice in psychedelic-assisted therapy, advocating for evidence-informed public education to clarify misconceptions about these substances. Overall, the legislation seeks to create a responsible approach to psychedelic policy in Massachusetts, prioritizing the unique needs of veterans while addressing the stigma and barriers to care.